

## Professor David Thickett DM FRCP

Professor in Respiratory Medicine

Cardiovascular and Respiratory Sciences

### Contact details

**Telephone** [+44 \(0\)121 371 3231](tel:+44%20121%20371%203231) (tel: +44 121 371 3231)

**Email** [d.thickett@bham.ac.uk](mailto:d.thickett@bham.ac.uk) (mailto:d.thickett@bham.ac.uk)

School of Clinical and Experimental Medicine  
College of Medical and Dental Sciences  
Centre for translational Inflammation Research  
University of Birmingham Laboratories  
Queen Elizabeth Hospital Birmingham  
Edgbaston, Birmingham, B15 2TT



### About

David Thickett trained in Oxford and London. He was a specialist registrar in the South West region before doing his DM thesis on ARDS in Bristol. He was initially appointed as a Senior Lecturer in 2001 and then became a Wellcome Intermediate Fellow in 2006. He was appointed as a reader in 2011 and promoted to Chair in Respiratory Medicine in 2014.

### Qualifications

MA (Oxon) DM FRCP

### Biography

#### General Professional training

1992 House Officer Surgery, Princess Royal Hospital  
1992-1993 House Officer Medicine, Professorial Department of Endocrinology, North Staffordshire Royal Infirmary, Stoke on Trent  
1993-1994 Senior House Officer Cardiothoracic Medicine, Harefield Hospital  
1994 Senior House Officer Clinical Oncology / Gastroenterology, Mount Vernon, Hospital  
1994-1995 Senior House Officer General / Respiratory Medicine, RUH, Bath  
1995 Senior House Officer Neurology, Royal United Hospital, Bath

#### Specialist training

1995-1996 Respiratory Registrar, Musgrove Park Hospital, Taunton  
1996-1998 Specialist Registrar Respiratory medicine, Southmead Hospital, Bristol  
1998-1999 Clinical Research Registrar, Lung Research Group, University of Bristol  
1999-2000 Specialist Registrar in Respiratory Medicine, Bristol Royal Infirmary  
2000-2001 Specialist Registrar, Gloucester Royal Hospital

#### Academic / Consultant Posts

2001-2006 Senior Lecturer in Medical Sciences, University of Birmingham and Honorary Consultant Physician, UHB  
2006-2011 Wellcome Intermediate Fellowship  
2011-2014 Reader in Respiratory Medicine  
2014 Professor in Respiratory Medicine

### Teaching

- Mentor for 9 medical students
- Regularly supervise BMEDSCI student projects (3rd year)
- Lead for speciality respiratory medicine 4th year
- Respiratory self select module in the second year

### Postgraduate supervision

- Previously had 4 MD students and 1 PhD student successfully complete
- Currently has 1 MD student and 4 PhD students

### Research

Dr Thickett's research interests are predominantly in the areas of primary lung epithelial and macrophage biology, murine models of acute lung injury, epithelial mesenchymal transition and translational clinical trials to prevent and treat acute lung injury and idiopathic pulmonary fibrosis. He has been and continues to be a co-investigator or principal investigator on a number of clinical trials successfully obtaining an MRC DCS grant for 2 clinical trials of vitamin D therapy to prevent lung injury following oesophagectomy.

Dr Thickett is currently involved in the following studies:

- translational science lead, chairman of clinical endpoints committee and steering group member for BALTI- PREVENTION
- PI of a phase II trial of simvastatin in healthy elderly patients

- PI of a phase II study of the pharmacogenetics of vitamin D replacement in tuberculosis
- PI of a phase II open label dosing study of vitamin D following oesophagectomy
- the PI of a phase II study vitamin D to prevent acute lung injury following oesophagectomy (VINDALOO)
- PI of a phase II study of simvastatin to modify neutrophil function in older patients with septic pneumonia (SNOOPI)
- TSC member of TIPAC-2 steering committee – a trial of septrin therapy in idiopathic pulmonary fibrosis

## Other activities

- Associate Editor of Thorax (2011-2015)
- Less than fulltime training committee representative for Respiratory Medicine West Midlands
- Respiratory Trainee training committee member 2006-ongoing
- Birmingham and the Black Country Respiratory research lead
- Represent respiratory Medicine for Birmingham upon the national Respiratory speciality group for the CLRN

## Publications

- Gates S, Perkins G, Lamb S, Kelly C, Thickett D, Young J, McAuley D, Snaith C, McCabe C, Hulme C, et al (2013) Beta-Agonist Lung injury Trial-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome. *Health Technol Assess* 17(38):1-88
- Parekh D, Dancer RC, Lax S, Cooper MS, Martineau AR, Fraser WD, Tucker O, Alderson D, Perkins GD, Gao-Smith F, et al (2013) Vitamin D to prevent acute lung injury following oesophagectomy (VINDALOO): study protocol for a randomised placebo controlled trial. *Trials* 14(1):100
- Parekh D, Thickett DR, and Turner AM (2013) Vitamin D deficiency and acute lung injury. *Inflamm Allergy Drug Targets* 12(4):253-61
- Patel JM, Thickett DR, Gao F, and Sapey E (2013) Statins for Sepsis: Distinguishing Signal from the Noise When Designing Clinical Trials. *Am J Respir Crit Care Med* 188(7):874
- Cooper MS, Thickett DR, and Stewart PM (2013) Reduced cortisol metabolism during critical illness. *N Engl J Med* 369(5):480
- Turner AM, and Thickett DR (2013) Molecular determinants of acute muscle wasting in the ICU: a role for growth and differentiation factor-15? *Crit Care Med* 41(4):1141-2
- Bartis D, Csongei V, Weich A, Kiss E, Barko S, Kovacs T, Avdicevic M, D'Souza VK, Rapp J, Kvell K, et al (2013) Down-regulation of canonical and up-regulation of non-canonical Wnt signalling in the carcinogenic process of squamous cell lung carcinoma. *PLoS One* 8(3):e57393
- Raghu G, and Thickett DR (2013) Pirfenidone for IPF: pro/con debate; the 'con' viewpoint. *Thorax* 68(7):605-8
- Jansen JO, Lord JM, Thickett DR, Midwinter MJ, McAuley DF, and Gao F (2013) Clinical review: Statins and trauma - a systematic review. *Crit Care* 17(3):227
- Mujakperuo H, McGrath EE, and Thickett DR (2013) Co-trimoxazole for idiopathic pulmonary fibrosis: time for TIPAC-2? *Thorax* 68(2):123-4

